Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00124657
Status:
COMPLETED
Last Update Posted:
2015-12-04
First Post:
2005-07-26
Brief Title:
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Sponsor:
St Jude Childrens Research Hospital
Organization:
St Jude Childrens Research Hospital
Study Overview
Official Title:
A Phase III Trial of a New Tyrosine Kinase Inhibitor Tarceva Erlotinib Hydrochloride OSI-774 During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiation therapy uses high-energy x-rays to kill tumor cells Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor It may also make tumor cells more sensitive to radiation therapy Giving radiation therapy together with erlotinib may kill more tumor cells
PURPOSE This phase III trial is studying the side effects and best dose of erlotinib when given together with radiation therapy and to see how well they work in treating young patients with newly diagnosed glioma
PURPOSE This phase III trial is studying the side effects and best dose of erlotinib when given together with radiation therapy and to see how well they work in treating young patients with newly diagnosed glioma
Detailed Description:
OBJECTIVES
Primary
Determine the maximum tolerated dose and dose-limiting toxicity of erlotinib when administered during and after radiotherapy in young patients with newly diagnosed high-grade glioma and unfavorable low-grade glioma
Determine the 1- and 2-year progression-free survival of patients treated with this regimen
Secondary
Determine the toxic effects of this regimen in these patients
Correlate genetic abnormalities in epidermal growth factor receptor EGFR and components of downstream pathways with treatment response in patients treated with this regimen
Determine the ability of erlotinib to inhibit EGFR signaling in patients with high-grade glioma who require second surgery
Determine the pharmacokinetics of erlotinib and its metabolites in these patients
Correlate plasma and cerebrospinal fluid levels of vascular endothelial growth factor and basic fibroblast growth factor with tumor response in patients treated with this regimen
Correlate irradiation dosimetry with patterns of failure standard and investigational imaging and toxicity in patients treated with this regimen
OUTLINE This is a phase I dose-escalation study of erlotinib followed by a phase II study
Phase I Patients undergo radiotherapy once daily 5 days week for approximately 6½ weeks Beginning on the first day of radiotherapy patients receive oral erlotinib once daily for up to 2 years
Cohorts of patients receive escalating doses of erlotinib until the maximum tolerated dose MTD is determined
Phase II Patients will receive erlotinib as in phase I at the MTD and undergo radiotherapy as in phase I
PROJECTED ACCRUAL A total of 75-80 patients 15-20 for the phase I portion and 60 for the phase II portion will be accrued for this study
Primary
Determine the maximum tolerated dose and dose-limiting toxicity of erlotinib when administered during and after radiotherapy in young patients with newly diagnosed high-grade glioma and unfavorable low-grade glioma
Determine the 1- and 2-year progression-free survival of patients treated with this regimen
Secondary
Determine the toxic effects of this regimen in these patients
Correlate genetic abnormalities in epidermal growth factor receptor EGFR and components of downstream pathways with treatment response in patients treated with this regimen
Determine the ability of erlotinib to inhibit EGFR signaling in patients with high-grade glioma who require second surgery
Determine the pharmacokinetics of erlotinib and its metabolites in these patients
Correlate plasma and cerebrospinal fluid levels of vascular endothelial growth factor and basic fibroblast growth factor with tumor response in patients treated with this regimen
Correlate irradiation dosimetry with patterns of failure standard and investigational imaging and toxicity in patients treated with this regimen
OUTLINE This is a phase I dose-escalation study of erlotinib followed by a phase II study
Phase I Patients undergo radiotherapy once daily 5 days week for approximately 6½ weeks Beginning on the first day of radiotherapy patients receive oral erlotinib once daily for up to 2 years
Cohorts of patients receive escalating doses of erlotinib until the maximum tolerated dose MTD is determined
Phase II Patients will receive erlotinib as in phase I at the MTD and undergo radiotherapy as in phase I
PROJECTED ACCRUAL A total of 75-80 patients 15-20 for the phase I portion and 60 for the phase II portion will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None